// App-Quantinova.ai

2133 : Ending the endless acquired tyrosine kinase resistance mutations Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R

Researchers

Presenter

  • J. Jean Cui

Principal Investigators

  • Evan Rogers

  • Dayong Zhai

  • Wei Deng

  • Zhongdong Huang

  • Jeffrey Whitten

  • Yishan Li

Medical Centers

  • TP Therapeutics, San Diego, CA

Locations

  • United States

Companies

  • Turning Point Therap

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • Anaplastic lymphoma Kinase

  • Neurotrophic Receptor Tyrosine Kinase 2

  • Neurotrophic tropomyosin receptor kinase

  • Proto-oncogene tyrosine-protein kinase ROS

  • Epidermal growth factor receptor

  • Threonine at amino acid position 790

Drug/Treatment

  • Entrectinib

  • Crizotinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved